Showing results (101-110 of 781) with videos related to
Sort By:
Pageof 79
Cancer Research|April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapyWeihua Song, Hans J J van der Vliet, Yu-Tzu Tai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Moving toward individualized cancer therapiesGiovanni Tonon, Kenneth C AndersonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2011
Disentangling the myeloma webGiovanni Tonon, Kenneth C AndersonCA: a Cancer Journal for Clinicians|October 1, 2014
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and backGiada Bianchi, Kenneth C AndersonHaematologica|October 15, 2020
Multiple myeloma: the (r)evolution of current therapy and a glance into futureAnnamaria Gulla, Kenneth C AndersonExpert Opinion on Drug Safety|February 27, 2020
The safety of current and emerging therapies for multiple myelomaOmar Nadeem, Kenneth C AndersonOncology (Williston Park, N.Y.)|June 7, 2005
Treatment options for older myeloma patients. From the Multiple Myeloma Research FoundationKenneth C Anderson, Antonio Palumbo, BMC Biology|November 1, 2011
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130CasDharminder Chauhan, Kenneth C AndersonInternational Journal of Hematology|September 2, 2011
Novel therapies in MM: from the aspect of preclinical studiesTeru Hideshima, Kenneth C AndersonPageof 79